Role of Gpcpd1 in intestinal alpha-glycerophosphocholine metabolism and trimethylamine N-oxide production.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and transgenic mouse study without human participants.
PubMed 39510189 · doi:10.1016/j.jbc.2024.107965
What was done
Researchers investigated the intestinal absorption and metabolism of alpha-glycerophosphocholine (GPC) using Caco-2 cell monolayer cultures and intestinal epithelial-specific Gpcpd1-deficient mice. In cell models, they measured apical hydrolysis of GPC, transport of choline, and the effect of Gpcpd1 siRNA knockdown on hydrolyzing activity. In vivo, they assessed intestinal GPC metabolism and circulating blood trimethylamine N-oxide (TMAO) elevations following GPC administration in Gpcpd1-knockout mice compared to controls.
What was found
Exogenous GPC was hydrolyzed to choline in the apical compartment of Caco-2 cells and transported to the basolateral medium. Gpcpd1 was present both intracellularly and in conditioned medium, and Gpcpd1 siRNA reduced GPC-hydrolyzing activity in both locations. Intestinal epithelial-specific deletion of Gpcpd1 in mice altered intestinal tissue GPC metabolism and partially blunted the increase in blood TMAO levels after GPC intake. Exact numerical values and effect sizes were not reported in the abstract.
Why it matters
This study identifies intestinal Gpcpd1 as a primary driver of luminal GPC conversion to choline, establishing a mechanistic link between GPC supplementation and downstream pro-atherosclerotic TMAO generation.
Limits
The findings are strictly preclinical, derived from cultured cell lines and mouse models, and cannot confirm human clinical outcomes. The abstract does not report sample sizes, specific quantitative measurements, or whether the partial reduction in TMAO is sufficient to alter cardiovascular disease risk.